SGLT2 Inhibitor Therapy in Type 2 Diabetes

Released On
December 10, 2020

Expires On
December 9, 2021

Media Type

Completion Time
30 minutes

Endocrinology, Primary Care


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Clinical Care Options, LLC.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Nurses — 0.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is primarily intended for endocrinologists, primary care physicians, and nurses who care for patients with T2D.

Program Overview

The goal of this activity is to improve learners’ competence and performance in SGLT2 inhibitor treatment decisions for patients with T2D with and without related comorbidities.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of SGLT2-I drugs in patients with varying degrees of CV and/or renal risk
  • Consider the key clinical evidence from CVOTs with SGLT2-I drugs in management decisions for patients with T2D



Anne Peters, MD

Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, California

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosures of Conflicts of Interest

Anne Peters, MD

  • Research Support : Abbott Diabetes Care, Dexcom, vTv Therapeutics
  • Ownership Interests : Livongo, Omada Health, Pendulum Therapeutics, Stability Health
  • Consultant: Abbott Diabetes Care, Bio-Rad, Lilly, MannKind, Merck, Novo Nordisk, Zealand


Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi, Inc.

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Participation and Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 10, 2020, through December 09, 2021:

  1. Register online at
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Site Viewing Requirements

  • Web browsers: Latest versions of Edge, Internet Explorer, Chrome, Firefox, and Safari
  • Mobile devices: Latest versions of Android and iOS
  • JavaScript Enabled. This website requires JavaScript to be enabled in your browser. To enable JavaScript, click here.
  • Cookie Enabled. This website requires cookies to be enabled in your browser. To enable cookies, click here.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions please contact: